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Abstract
Dexamethasone (Dexa) is a widely used glucocorticoid to treat inflammatory diseases; however, a multitude of undesired
effects have been reported to arise from this treatment including osteoporosis, obesity, and in children decreased
longitudinal bone growth. We and others have previously shown that glucocorticoids induce apoptosis in growth plate
chondrocytes. Here, we hypothesized that Bax, a pro-apoptotic member of the Bcl-2 family, plays a key role in Dexa-induced
chondrocyte apoptosis and bone growth impairment. Indeed, experiments in the human HCS-2/8 chondrocytic cell line
demonstrated that silencing of Bax expression using small-interfering (si) RNA efficiently blocked Dexa-induced apoptosis.
Furthermore, ablation of Bax in female mice protected against Dexa-induced bone growth impairment. Finally, Bax
activation by Dexa was confirmed in human growth plate cartilage specimens cultured ex vivo. Our findings could therefore
open the door for new therapeutic approaches to prevent glucocorticoid-induced bone growth impairment through
specific targeting of Bax.
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Introduction
Glucocorticoids (GCs) are widely used to treat inflammatory
and autoimmune conditions, including a variety of life-threatening
and disabling disorders. In the UK alone, more than 250,000
people are taking systemic steroids for various conditions, and at
least 10% of all children require some form of GCs treatment
during childhood [1]. One of the undesired side effects of
Dexamethasone (Dexa), a widely used GC, is its ability to cause
growth retardation in treated children [2]. It is well known that
GC treatment decreases longitudinal bone growth by inhibiting
chondrocyte proliferation, hypertrophy, and cartilage matrix
production [3,4], but the exact molecular mediators behind these
effects are poorly understood. Undesired apoptosis could be an
additional underlying mechanism involved in GC-induced growth
impairment. GCs are known to induce apoptosis and reduce cell
proliferation in different cell types, including chondrocytes,
muscle, bone cells, and thymocytes [5,6,7,8,9,10,11,12]. Although
experimental data have shown that Dexa treatment may trigger
apoptosis within the growth plate [3,4,13,14,15], the molecular
mechanisms of GCs-induced apoptosis and its role in bone growth
impairment remain elusive.
Longitudinal bone growth is a dynamic process of proliferation,
differentiation and cell death that is regulated by different
hormones [16]. Previous studies have revealed that disturbed
chondrocyte activity within the growth plate, due to either
disruption in normal cell proliferation or unscheduled apoptosis,
may lead to defective longitudinal bone growth [17]. Apoptosis, a
form of programmed cell death, plays a central role in tissue
homeostasis, and deregulation of apoptosis has been implicated in
numerous pathological conditions [18]. In mammalian cells, two
major apoptotic signaling pathways exist, including the intrinsic
pathway, which is dependent on the mitochondria, and the
extrinsic pathway, which is regulated through so-called death
receptors on the cell surface [19,20]. A wide range of signals can
trigger the intrinsic pathway, including cellular stress, radiation,
cytotoxic drugs and lack of essential growth factors, which may
cause release of apoptogenic proteins, such as cytochrome c, from
mitochondria [21]. These events result in the activation of a
cytosolic caspase cascade, which leads to the morphological
changes associated with apoptosis. The Bcl-2 family of proteins
control permeabilization of the outer mitochondrial membrane
and thereby regulate the activation of caspases [22]. According to
the so-called rheostat model of apoptosis regulation, the relative
amounts of pro-apoptotic versus pro-survival members of the Bcl-2
family are critical determinants of the intrinsic cell death pathway
[23]. The pro-apoptotic Bax protein is regulated by phosphory-
lation in an Akt-dependent manner, and this phosphorylation
event inhibits the effects of Bax on mitochondria by maintaining it
in the cytoplasm [24].
We have previously reported that Dexa-induced apoptosis in
chondrocytes is mediated through suppression of the PI3K-Akt
signaling pathway and activation of the caspase cascade (caspases
3, 8 and 9) [5]. Although caspase-8 is often thought to be activated
exclusively through the death receptor pathway, recent studies
show that activation of caspase-8 can also occur in a mitochon-
dria-dependent manner that is independent of the Fas-associated
death domain (FADD) [25,26]. Moreover, we reported that Dexa
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Taken together, this led us to hypothesize that the intrinsic
apoptotic pathway may play a key role in Dexa-induced apoptosis
in growth plate chondrocytes. Using an array of different in vitro
and in vivo model systems, we here demonstrate a functional role of
Bax, a key mediator of intrinsic apoptosis, in GC-induced bone
growth impairment. These results have important implications for
the development of preventive strategies aiming to rescue
longitudinal bone growth in patients receiving GC treatment
during childhood.
Results
Bax deficiency protects young mice from Dexa-induced
bone growth impairment
Based on the assumption that Bax plays a key role regulating the
intrinsic apoptotic signaling pathway in chondrocytes exposed to
Dexa, one would predict that Bax-deficient mice are resistant to
Dexa-induced growth retardation. To validate this hypothesis, Bax
knockout (BaxKO) and wild type mice (males and females) were
treated with a clinically relevant dose of Dexa (2 mg/kg body
weight/day) or vehicle for 28 days. In wild-type female mice, Dexa
treatment reduced femur growth by 47% (p,0.001 vs. vehicle)
while in BaxKO female mice growth was only suppressed by 8%
when treated with Dexa (not significant, vs. vehicle; Figure 1A).
The growth rescuing effect observed in Dexa treated BaxKO
female mice was found to be significant when compared to wild
type animals (p,0.01 vs. wild-type Dexa; Figure 1A). Also in male
mice, Dexa caused a significant growth impairment in wild type
animals (50% reduction; p,0.001 vs. vehicle), whereas BaxKO
males were less protected from Dexa-induced growth impairment
(22% reduction; p=0.4 vs. females; Figure 1A–B). A similar
pattern was seen when calculating femur growth velocity which
was profoundly suppressed by Dexa in wild-type female and male
mice, whereas Bax-deficient animals were much less affected
(Figure 1C and 1D). Indeed, after 21 days BaxKO Dexa treated
females showed a higher femur growth velocity than wild type
females treated with Dexa (Figure 1C). Altogether, our data clearly
show that BaxKO mice are protected from the negative effects of
Dexa treatment on longitudinal bone growth. While the protection
from Dexa-induced bone growth impairment seemed to be more
pronounced in females, the difference between the two genders did
not reach statistical significance.
Also body weight was affected in a similar way where BaxKO
animals were less sensitive to Dexa treatment. When assessed after
4 weeks, body weight in wild type mice was 16.060.4 g in Dexa
while 17.860.3 g in the vehicle group (p,0.01), a difference
which was less pronounced in BaxKO female animals (16.060.3 g
body weight in Dexa vs. 16.860.2 g in vehicle; not significant,
p.0.2).
Apoptosis and chondrocyte proliferation in growth
plates of BaxKO mice
The precise balance between cell proliferation and apoptosis
within growth plate cartilage is a key regulator of normal bone
growth. Therefore, to understand the mechanism(s) behind the
protective effect of Bax-deficiency on Dexa-induced bone growth
impairment, apoptosis (TUNEL staining), cell proliferation (BrdU-
incorporation), matrix content (Alcian Blue staining), and
morphology were studied in tibial growth plates from wild-type
and BaxKO female mice. We found that Dexa treatment
significantly increased the number of apoptotic chondrocytes in
growth plates of wild-type mice (p,0.01; a 2.5-fold increase vs.
vehicle; Figure 1E), while in BaxKO female mice no such effect
was detected demonstrating that those animals were protected
from Dexa-induced apoptosis (Figure 1E). Furthermore, Dexa
treatment caused a strong suppression of chondrocyte proliferation
in growth plates of wild-type mice (P,0.001) while BaxKO
animals were protected from this effect (Figure 1F). Dexa
treatment increased the loss of glycosaminoglycan (GAG) into
the serum in wild type animals (p,0.001 vs. vehicle), while no
effect was observed in BaxKO animals (Figure 2A–B). In addition,
Dexa-treatment slightly decreased chondrocyte column density in
wild-type mice (not significant), an effect which was not seen in
BaxKO animals (Supplementary Information Figure S1). These
data were validated in 7-week-old male rats treated with Dexa
(5 mg/kg body weight/day) for 7 days confirming decreased tibia
growth plate height (Figure 2C–D) and reduced chondrocyte
column density (Figure 2E).
In summary, Bax-deficiency not only protected mice from
Dexa-induced chondrocyte apoptosis but also maintained chon-
drocyte proliferative capacity, matrix content and growth plate
integrity, which may explain how the growth of these animals is
rescued during Dexa treatment.
Bax ablation rescues chondrocytes from Dexa-induced
apoptosis
The protective effects of Bax-deficiency against Dexa-induced
bone growth impairment demonstrated a critical role of this
protein. To clarify any involvement of chondrocytes to mediate
these effects, studies were performed in the human chondrocytic
cell line, HCS-2/8. These cells exhibit characteristics of both
proliferative and hypertrophic growth plate chondrocytes when
kept under specific culture conditions. Experiments conducted in
proliferative HCS cells revealed that 72 hrs of Dexa (25 mM)
treatment markedly increased the expression of Bax (3-fold
increase vs. control; p,0.001; Figure 3A). Co-administration of
Dexa (25 mmol/L) and IGF-I (100 ng/ml) decreased Bax
expression by 40% compared to Dexa alone (p,0.01;
Figure 3A). Furthermore, Bcl-2 protein levels were significantly
decreased in Dexa treated cells (p,0.05 Dexa vs. Control;
Figure 3B). To investigate if up-regulation of Bax is a critical step
in Dexa-induced chondrocyte apoptosis, Bax expression was
suppressed using specific siRNAs. Proliferative HCS cells were
transfected with Bax siRNAs and treated with Dexa (25 mmol/L)
for 72 hrs. In non-silenced, control cells, Dexa increased apoptosis
by 59% (p,0.001 vs. control); however, transfection with Bax
siRNAs completely rescued chondrocytes from Dexa-induced
apoptosis (p,0.001 vs. Dexa alone; Figure 3C), an effect similar to
what was observed in BaxKO animals. Bax-specific siRNA
completely suppressed the expression of Bax as shown in
Figure 3D. These data suggest that Bax-deficiency in chondrocytes
may help to protect the growth plate cartilage and longitudinal
bone growth from the negative effects of GCs.
Dexa treatment induces conformational changes in Bax
In other cell systems, conformational changes in Bax, and its
resulting translocation to mitochondria, have been reported to be
associated with a decrease in mitochondrial membrane potential
[15]. However, in chondrocytes it is still unknown whether GC
treatment can induce conformational changes in Bax. To address
this key question, we used a specific antibody that detects only
conformationally changed Bax (clone 6A7). HCS cells treated with
Dexa for 72 hrs displayed strong mitochondrial Bax staining
supporting translocation of Bax towards the mitochondrial
membrane (Figure 4A). We further asked whether the observed
Bax activation is due to local/direct effects of GC treatment in the
growth plate cartilage. To address this, we applied an organ
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PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33168Figure 1. Bax deficiency protects mice from Dexa-induced bone growth impairment. Bax knockout (BaxKO) and wild-type female and
male mice were treated with Dexa (2 mg/kg body weight/day) or saline for 28 days. X-ray images were captured on days 0, 7, 14, 21, and 28, and left
femur lengths were measured. Femur bone length increase from day 0 in (A) female mice (***p,0.001, wild type Dexa vs. wild type vehicle;
**p,0.01, wild type Dexa vs. BaxKO Dexa; n=5) and (B) male mice (***p,0.001, wild type Dexa vs. wild type vehicle., n.s=not significant; n=5.).
Femur growth velocity (mm/day) in (C) female mice (***p,0.001, wild type Dexa vs. wild type vehicle.,**wild type Dexa vs. BaxKO Dexa., n=5) and (D)
male mice (***p,0.001, *p,0.05, wild type Dexa vs. wild type vehicle; n=5). (E) TUNEL assays for the detection of apoptotic chondrocytes in growth
plates of BaxKO and wild-type female mice treated with Dexa or vehicle for 28 days (**p,0.01, wild type Dexa vs. wild type vehicle., **p,0.01, wild
type Dexa vs. BaxKO Dexa, n=5). (F) BrdU incorporation analysis for the assessment of chondrocyte proliferation in growth plate cartilage of BaxKO
and wild-type female mice treated with Dexa or saline for 28 days. (***p,0.001, wild type Dexa vs. wild type vehicle; **p,0.01, wild type Dexa vs.
BaxKO Dexa; n=5).
doi:10.1371/journal.pone.0033168.g001
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Dexa (1 mmol/L) for 12 days. Bones exposed to Dexa displayed
pronounced growth retardation (Figure S2) and increased Bax
expression in growth plate chondrocytes, as determined by
fluorescent immunohistochemistry (Figure 4B). To complement
these in vitro studies, rats were treated with Dexa documenting a
strong mitochondrial Bax staining in tibial growth plate chondro-
cytes which contrasted to vehicle treated controls where no
staining was observed (Figure 4C).
Mitochondrial membrane potential and cytochrome c
release in chondrocytes
After identifying the conformational changes in Bax and its
subsequent translocation to mitochondria, we measured changes in
the mitochondrial membrane potential in chondrocytic HCS cells.
As seen in Figure 5A, the mitochondrial membrane potential was
significantly suppressed after 24 and 48 hrs of Dexa exposure
(p,0.001 vs. control). To address if Dexa treatment also leads to
mitochondrial release of cytochrome c into the cytosol, HCS cells
were treated with Dexa for 24, 48 and 72 hrs and fractionated into
mitochondrial and cytosolic extracts followed by quantification of
cytochrome c. Dexa treatment increased cytochrome c release at 24
and 48 hrs by 45% and 43%, respectively (p,0.01 vs. control), and
co-treatment with a known anti-apoptotic growth factor, insulin-like
growth factor-I (IGF-I; 100 ng/ml), partially prevented this (21%
reduction compared to Dexa alone at 24 hr; p,0.01 vs. Dexa alone)
(Figure 5B). Cytochrome c release was also confirmed by
immunocytochemistry of treated cells (Figure 5C). In untreated
cells, cytochrome c was largely localized in the mitochondria, while
in Dexa-treated cells cytochrome c was mainly localized in the
cytoplasm. To quantify cytochrome c release, Dexa-treated
chondrocytes were fractionated into mitochondrial and cytosolic
extracts and measured by ELISA. Dexa alone increased cytosolic
cytochromecby57%(p,0.01vs.control)whereasBaxablationwith
siRNAs completelypreventedDexa-induced release of cytochromec
(p,0.01 vs. Dexa-treated cells) (Figure 5D). These data suggest that
Bax is a key player involved in the modulation of cytochrome c
release which in turn triggers intrinsic apoptosis in chondrocytes.
Figure 2. Loss of matrix and growth plate height. (A) Tibial growth plate sections from female mice were stained with Alcian Blue to detect any
alterations in matrix content within the growth plate cartilage. In wild-type mice, Alcian Blue staining appeared to be weaker in Dexa-treated animals
compared to those treated with vehicle, while in BaxKO no such effect was seen. Furthermore, in Dexa-treated wild-type animals growth plate height
appeared to be reduced and chondrocyte columns disorganized. To quantify any changes in matrix content, (B) loss of GAG was measured in the
serum demonstrating significantly increased GAG release in Dexa treated wild type mice (*p,0.05, vs. wild type vehicle., n=5). In contrast, BaxKO
animals were protected from Dex-induced release of GAG (**p,0.01, vs. wild type Dexa; n=5) (C) Representative micrographs of rat growth plate
(tibia) showing different zones affected by Dexa; resting+proliferative (R+P) and hypertrophic (H) zones (bars represent 50 mm). Quantitative
histological analysis of (D) growth plate height and (E) chondrocyte column density (columns per mm growth plate width) in vehicle- and Dexa-
treated rats (**p,0.01, ***p,0.001; n=6).
doi:10.1371/journal.pone.0033168.g002
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Finally, to corroborate the findings obtained in mice in vivo,i n
organ cultures of fetal rat metatarsal bones, and in a human
chondrocytic cell line, studies were performed in cultured human
growth plate cartilage. Growth plate tissue biopsies collected from
tall children (13–15 years old) undergoing epiphyseal knee surgery
to stoptheir continued leg growth, were treatedwithDexa (1 mmol/
L) for 24 hrs. Applying a Bax antibody that detects conformation-
ally changed Bax, we observed increased Bax activation in Dexa-
treated human growth plate cartilage (p,0.01 vs. control;
Figure 6A–B). These data support Bax involvement in Dexa-
induced bone growth impairment also in humans.
Discussion
Here, we provide in vivo evidence that apoptosis in growth plate
chondrocytes plays a significant role in GC-induced growth
retardation. In addition, we show that the pro-apoptotic protein,
Bax is a key player in this undesired apoptosis. The disorganiza-
tion of growth plate morphology normally seen in Dexa-treated
animals did not occur in Bax-deficient animals. Bax deficiency
preserved chondrogenesis and rescued bones from Dexa-induced
growth impairment.
We present evidence that Bax deficiency protects the growth
plate from many of the undesired effects of GCs. Most striking is
Figure 3. Bax ablation rescues chondrocytes. Proliferative HCS chondrocytic cells treated with Dexa (25 mM) for 72 hrs were analyzed for the
expression of the (A) Bax and (B) Bcl-2 proteins. (C) Bax ablation protected proliferative chondrocytes from Dexa-induced apoptosis. HCS-2/8
chondrocytic cells in proliferative phase were transfected with Bax-specific siRNAs (80 pmol) for 48 hrs prior to incubation with Dexa (25 mmol/L) for
an additional 72 hrs. Suppression of Bax completely rescued chondrocytes from Dexa-induced apoptosis. Apoptosis was measured by using the Cell
Death Detection ELISA
PLUS kit. (D) Western immunoblotting showing suppression of Bax in Dexa-treated HCS-2/8 chondrocytic cells transfected with
Bax-siRNA.
doi:10.1371/journal.pone.0033168.g003
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PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33168Figure 4. Conformational changes in Bax and translocation to mitochondria. (A) Immunocytochemistry of HCS cells in proliferation phase,
treated or untreated with Dexa (25 mM) for 72 hrs. Cells were analyzed for conformational changes in Bax using a specific antibody that only detects
conformationally altered Bax. Chondrocytes were labeled with Bax antibody (red) and MitoTracker (green). Bax was mainly found in the mitochondria
of Dexa-treated cells, as shown by the yellow-orange staining that is due to the merged red and green fluorescence. (B) Cultured fetal rat metatarsal
bones treated with Dexa stained for DAPI (blue) and conformationally altered Bax (Conf- Bax; red). (C) Growth plate sections (tibia) of 7-week-old rats
treated with Dexa (5 mg/kg/day) for 7 days. Immunohistochemistry was performed by triple-fluorescent labeling for conformationally changed Bax
(Conf- Bax; red), HSP60 antibody (green), and DAPI (nuclei; blue). Conformationally changed Bax was mainly found in the chondrocyte mitochondria
of those animals treated with Dexa, as shown by the yellow-orange staining that is due to the merging of red and green fluorescence.
doi:10.1371/journal.pone.0033168.g004
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33168the strong bone growth rescuing effect observed in Dexa-treated
female Bax-deficient/BaxKO mice. Longitudinal bone growth
was severely impaired in Dexa-treated female wild-type mice
while Bax-deficient females were protected. These findings are in
accord with the previous report by Perez et al. [27] describing
the alleviation of age-related bone loss in female mice following
inactivation of the Bax gene [27]. Interestingly, Dexa treated
Bax-deficient female animals showed a pattern of late catch-up
growth while still being exposed to Dexa and eventually
displayed a growth velocity which even exceeded that observed
in vehicle treated Bax-deficient females, suggesting that the
groups might even reach a comparable size if followed for a
longer time. When compared to females, we observed that Bax-
deficient male mice were less protected against GC-induced
bone growth impairment. The observed sex difference could be
due to the fact that infertility and testicular atrophy have been
reported in Bax-deficient male mice [28]. Androgens have
indeed been shown to modulate bone growth and bone mass in
rats [29], and in men testicular atrophy has been linked to
osteoporosis [30].
Figure 5. Dexa triggers dissipation of mitochondrial membrane potential and cytochrome c release in human proliferative
chondrocytes. (A) Proliferative HCS-2/8 chondrocytic cells were treated with Dexa (25 mM) for 12, 24 and 48 hrs. Mitochondrial membrane potential
was significantly decreased after 24 and 48 hrs in those chondrocytes treated with Dexa (***p,0.001 vs. untreated control). (B) HCS cells (treated or
untreated with Dexa) were fractionated into cytosolic and mitochondrial extracts, and cytochrome c levels were determined in the cytosolic fractions.
Cytochrome c was significantly increased following treatment with Dexa (25 mM) when assessed after 24, 48 and 72 hrs (***p,0.001 vs. untreated
control). IGF-I (100 ng/ml) prevented Dexa-induced cytochrome c release at 24 hrs (**p,0.01 vs. Dexa alone), but failed to do so after 48 and 72 hrs.
(C) Immunohistochemistry of cytochrome c release from mitochondria of HCS cells that were treated for 72 hrs with 25 mM Dexa or vehicle (99%
EtOH). Cells were stained to visualize mitochondria (MitoTracker; green), cytochrome c (red), and nuclei (DAPI; blue). Cytochrome c was mainly found
to be localized in the mitochondria (merged image-yellow) of control cells, while cytochrome c was evident in the cytosol of Dexa-treated HCS cells
(shown as red fluorescence (arrows)). (D) Cytochrome c release was completely blocked by Bax siRNAs in transfected HCS-2/8 cells (**p,0.01; n=4).
doi:10.1371/journal.pone.0033168.g005
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e33168While Dexa treatment of wild-type female mice markedly
increased chondrocyte apoptosis, decreased cell proliferation, and
suppressed matrix production in the growth plate, no such effects
were observed in Bax-deficient females exposed to Dexa. All these
effects may contribute to the growth rescuing effect observed in
Dexa-treated Bax-deficient female animals. However, we believe
apoptosis prevention to be the most important mechanism as Bax-
deficiency primarily impairs the intrinsic apoptotic pathway [22].
Furthermore, chondrocyte proliferation rate was found to be
rather slower in vehicle-treated Bax-deficient female mice
Figure 6. Activation of Bax in human growth plate cartilage. Human growth plate biopsies from children undergoing epiphyseal surgery to
reduce their longitudinal bone growth were treated with Dexa (1 mmol/L) and vehicle (99% EtOH) for 24 hrs. (A) Immunohistochemistry for the
detection of conformationally altered active Bax was performed using a specific anti-Bax antibody (clone 6A7). (B) Quantification of percent cells
staining positive for conformationally altered Bax (*p,0.05, n=4).
doi:10.1371/journal.pone.0033168.g006
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maintained in Dexa treated Bax-deficient mice and that
chondrocytes do not undergo cell death to the same degree as in
wild-type animals exposed to Dexa. Furthermore, loss of GAG
into the serum, a sign of matrix degradation, was increased in wild
type Dexa animals but not affected in Bax-deficient Dexa animals.
We found intense Alcian Blue staining in the matrix of BaxKO
animals which is likely due to higher numbers of surviving and
proliferating chondrocytes producing matrix in the growth plates
of those animals. Previous studies showed that under in vitro
conditions in ATDC-5 chondrocytes, protein content increased
with increase in cell number as well as extracellular matrix,
whereas Dexa decreased the protein content of cultures while cell
proliferation was inhibited [31]. In contrast, GCs at low doses
have also been reported to prevent the loss of GAG caused by
TNF-a in cultured cartilage explants [32]. Taken together, the
dual role of GCs on matrix content in bone tissue appears to be
time- and dose-dependent.
Applying different model systems, we demonstrate that Dexa
activates the mitochondrial intrinsic apoptotic pathway in growth
plate chondrocytes triggering Bax translocation and cytochrome c
release in these cells. These actions of Dexa have not been
described previously in chondrocytes, although in other cell model
systems translocation of Bax to mitochondria is known to be an
important step in the release of cytochrome c from mitochondria
to the cytosol [22]. Cytochrome c in turn is an important co-factor
for activation of caspases that act downstream of mitochondria c in
response to apoptotic signals [18]. We and others have previously
reported that increased apoptosis and altered cell proliferation/
differentiation contribute to Dexa-induced bone growth impair-
ment [5],[13]. Proliferative chondrocytes in the growth plate
cartilage play a crucial role in the longitudinal bone growth
process as these cells proliferate and differentiate into hypertrophic
chondrocytes where their intracellular volume is dramatically
increased [33]. Any disturbance in the cellular activity of
proliferative chondrocytes may therefore have great impact on
bone growth. We therefore decided to use proliferative chondro-
cytes (human HCS-2/8 chondrocytic cells) when dissecting the
cellular mechanisms of Dexa-induced bone growth impairment. In
vivo experiments were performed in rats and young mice, and ex
vivo studies in organ cultures of fetal rat metatarsal bones and
unique human growth plate biopsies. These complementary
studies consistently confirmed that Bax undergoes conformational
changes in growth plate chondrocytes when Dexa treated, clearly
indicating that Bax plays a key role to trigger undesired growth
plate chondrocyte apoptosis. Our conclusions are further support-
ed by previous data from other model systems, including
osteoblasts and mouse neural precursor cells, in which Bax has
been demonstrated to undergo conformational changes upon
activation, thereby triggering apoptosis [34,35]. We have reported
previously that Dexa treatment leads to suppression of Akt
phosphorylation in HCS cells [5]. In other model systems such as
neutrophils, Bax has been reported to be regulated by phosphor-
ylation of serine184 in an Akt-dependent manner [24]. Phosphor-
ylation inhibits the effects of Bax on mitochondria by maintaining
Bax in the cytoplasm [24]. It is therefore likely that Dexa-induced
activation of Bax reported herein is associated with suppressed Akt
phosphorylation.
The present study provides strong evidence based on multiple
approaches that Bax plays a major role in Dexa-induced apoptosis
in chondrocytes. Moreover, Espina et al. [36] reported that gene
silencing of Bax or the upstream BH3-only protein Bim both
reduced apoptosis induced by Dexa in murine osteoblasts.
However, we cannot rule out the existence of other minor
pathways leading to apoptosis not involving Bax. We previously
reported that Dexa triggers caspase-dependent apoptosis in the
HCS-2/8 chondrocytic cell line with early activation of caspase-8
[5] and caspase-8 could, in principle, activate downstream effector
caspases including caspase-3 directly without engagement of the
mitochondrial amplification loop [18]. Notwithstanding, Bax
appears to be a key player, as evidenced by the significant
protection seen in BaxKO animals.
The present observation that Bax-deficient mice are resistant to
Dexa-induced bone growth impairment is of considerable clinical
relevance and could have wider implications. For example,
cartilage tissue specimens from rheumatoid arthritis patients have
higher levels of Bax than in samples from healthy controls [37].
The significance of our findings for bone physiology is further
supported by previous mouse studies showing that Bax deficiency
is associated with increased bone mineral density (BMD) [27] and
increased cartilage production [38]. These observations suggest
that decreased levels of Bax may provide further protection to the
bone tissue against GCs toxicity. We propose that future treatment
strategies based on targeted suppression of Bax should be explored
in disease specific conditions such as chronic inflammation where
GCs are widely used. Use of small molecules/peptides with anti-
Bax activity such as humanin [39,40], can be one feasible
approach to block negative effects of GCs in normal tissues [41].
Interestingly, Bax knockout animals do not spontaneously develop
tumors or any other health complications, except for the fact that
the males are infertile [27].
In conclusion, we have shown that Dexa activates the pro-
apoptotic protein Bax in growth plate chondrocytes and that Bax
plays a key role in the pathogenesis of Dexa-induced bone growth
impairment by triggering apoptosis and premature loss of growth
plate chondrocytes. We also found Bax-deficient mice to be
significantly protected from Dexa-induced chondrocyte apoptosis
and bone growth impairment further supporting a crucial role of
Bax in mediating these undesired effects of Dexa. In unique
human growth plate tissue samples, we confirmed Bax-activation
after treatment with Dexa emphasizing the importance of Bax as
a key regulator of longitudinal bone growth. Our data suggest
that therapeutic targeting of Bax may offer a potential strategy
to prevent GC-induced bone growth impairment in treated
children.
Materials and Methods
Ethics statement
The human growth plate tissue collection was approved by the
local human ethics committee (Karolinska Institutet Research
Ethics Committee North at the Karolinska Hospital). According to
this approval, verbal informed consent was obtained from each
subject and his/her parents which was documented in the original
hospital records.
Animal studies were approved by the local animal ethics
committee (Stockholm North Animal Ethics Committee, permits
number Dnr N74/08, N389/07 and N29/08).
Human growth plate biopsies
Human growth plate biopsies were collected from the tibial
growth plates of four tall boys (13–15 years old) who underwent
epiphyseal surgery to arrest longitudinal bone growth. Immedi-
ately after collection, the biopsies were cut into small pieces and
transferred into a DMEM-high glucose 16medium (cat # 21063,
Invitrogen, Scotland) with the same additives as the medium used
for metatarsal bone cultures. Biopsies were treated with Dexa
(1 mM) or vehicle (99% EtOH) for 24 hrs, fixed in 4%
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paraffin blocks.
Maintenance and treatment of Bax-deficient mice
Heterozygous, Bax-deficient C57BL/6 mice [28] were obtained
from Jackson Laboratories (Bar Harbor, ME), and breeding was
performed to obtain homozygous animals. Genotyping was done
as described by Jackson Laboratories, and homozygous (male and
female) 30–32 day-old mice received a daily subcutaneous
injection (in the neck) with vehicle (0.1 ml saline) or Dexa
(2 mg/kg body weight) for 28 days. The mice were weighed, and
bones were measured every week by X-ray (AMX-4, GE Medical
Systems, WI). All animals received an intraperitoneal injection
with BrdU (10 mg/ml; 200 ml), 15 minutes and 2 hrs before
sacrifice. The femur and tibia were carefully dissected, cleared
from muscle and immediately fixed in 4% formalin for 48 hr at
4uC. Four sections were mounted on each slide, one from each
group, so that all samples were treated under the same conditions.
Measurement of sGAG in serum
To measure the loss of matrix content in serum, we used
sulphated glycosaminoglycans (sGAG)-kit (Euro-Diagnostica AB,
Malmo ¨, Sweden), a quantitative dye-binding assay for the in vitro
analysis of sGAG. This assay can be used to detect sGAGs in
biological samples such as synovial fluid, blood, and tissue extracts.
The amount of proteoglycans can be reliably and conveniently
quantitated with the Alcian Blue method which is highly specific
for the sulfated glycosaminoglycan chains on the proteoglycans.
Serum samples from both wild type and BaxKO animals were
analyzed for loss of sGAG according to instructions provided by
the manufacturer with the kit.
Reagents
Dexa and IGF-I (Sigma-Aldrich, Steinheim, Germany) were
dissolved in ethanol or saline, according to the manufacturer’s
instructions. Trypsin, phosphate buffered saline (PBS), fetal bovine
serum (FBS), EDTA, MEM alpha medium, and DMEM/F12
medium were all purchased from Invitrogen (Paisley, Scotland).
Cell culture and treatment
The human chondrosarcoma-derived chondrocytic cell line,
HCS-2/8 [42], was maintained in D-MEM/F12 medium
supplemented with 20% FBS, as previously described [5].
Immunoblotting
Following incubation, HCS-2/8 cells were lysed in RIPA buffer
and protein levels were measuredusing the Bradford assay (Bio-Rad
Laboratories AB, Sundbyberg, Sweden). Cell extracts were
subjected to SDS-PAGE, electrophoretically transferred to nitro-
cellulose membranes and subsequently incubated with primary
antibodies against Bax (1:1000), Bcl-2 (1:1000) (Santa Cruz
Biotechnology, Santa Cruz, CA). The membranes were incubated
overnight at 4uC, washed with 16 TBS-T and incubated with
HRP-conjugated secondary antibodies. The signals were detected
using the ECLplus chemiluminescence detection system. Bax
expression in HCS-2/8 cells was determined using specific anti-
Bax antibodies (Santa Cruz Biotechnology, Santa Cruz, CA).
DNA fragmentation analyses
The detection and quantification of cytoplasmic, histone-
associated DNA fragments (Cell Death Detection ELISA
PLUS,
Roche Diagnostics GmbH, Germany) was performed as previ-
ously described [5].
Mitochondrial membrane potential
A total of 4.0610
5 HCS-2/8 cells were cultured in each well
and treated with Dexa (25 mM) for 12, 24 or 48 hrs. After
treatment with Dexa, cells were collected by trypsinization,
washed with PBS, resuspended in DMEM-F12 medium contain-
ing tetramethylrhodamine ethyl ester (TMRE, 100 nmol) and
incubated at 37uC for 60 min. Cell suspensions were then
subjected to analyses using an ELISA reader (450 nm absorbance,
570 nm reference) to detect any dissipation of the mitochondrial
membrane potential.
Cytochrome c release
HCS cells were fractionated into cytosolic and mitochondrial
fractions and analyzed for the release of cytochrome c into the
cytosol using the cytochrome c ELISA kit (R&D systems)
according to the instructions provided by the manufacturer.
Briefly, cells (2610
6) were treated with Dexa (25 mM) and IGF-1
(100 ng/ml) for different time periods and collected by centrifu-
gation. After centrifugation, cells were washed with 16DPBS and
lysed in cell lysis buffer (10 mM HEPES (pH 7.4), 250 mM
mannitol, 10 mM KCl, 5 mM MgCl2, 1 mM EGTA) containing
1 mM PMSF and a mixture of protease inhibitors (Roche
Molecular Biochemicals). The cells were homogenized in lysis
buffer with 30 strokes of a Dounce homogenizer using a B-type
pestle. The homogenates were centrifuged at 8006g for 10 min to
remove nuclei and cell debris. The resulting supernatant was
collected in a new Eppendorf tube and centrifuged at 14,0006g
for 30 min at 4uC, which yielded cytosolic supernatant fractions
and mitochondria-containing pellets that were analyzed for the
presence of cytochrome c.
Small-interfering RNAs
Human HCS-2/8 chondrocytic cells were transfected with a
double-stranded siRNA oligonucleotide designed to interfere with
the expression of human Bax (Santa Cruz Biotechnology). A
scrambled, non-specific siRNA was used as a negative control.
Cells were cultured in DMEM-F12 medium supplemented with
20% FBS 24 hr prior to the transfections. On day 2 of culture,
siRNAs were added and the cells were then cultured for another 2
days (48 hrs) in DMEM-F12 with 1% FBS. After 48 hrs of
transfection, cells were treated with Dexa for 72 hrs and the
amount of cell death was determined using the cell death detection
ELISA kit (see above). Gene silencing was confirmed by western
blotting.
Metatarsal organ cultures
Three middle metatarsal bone rudiments were dissected out
from the paws of day E20 rat embryos and cultured as previously
described [43]. All experiments were approved by the local ethical
committee at Karolinska Institutet.
TUNEL and BrdU incorporation assay
Apoptotic cells were identified by terminal deoxynucleotidyl
transferase (TdT)-mediated deoxy-UTP nick end labeling (TU-
NEL) by using a DNA fragmentation kit (Oncogene Research,
Boston, MA). Growth plate chondrocyte proliferation was
analyzed by a BrdU cell proliferation kit (Amersham Biosciences,
Buckinghamshire, UK) and digital automatic cell counting was
performed as previously described [44].
Flourescence microscopy of cells
Staining of cytochrome c and Bax in HCS cells was performed
using anti-cytochrome c antibody or anti-Bax antibody (clone 6A7)
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5) were grown
on glass coverslips and allowed to attach by overnight incubation
at 37uC. The next day, cells were exposed to Dexa or IGF-1 for
the indicated times. Cells were washed with PBS, fixed in 4%
paraformaldehyde for 15 min at 4uC, permeabilized with 0.1%
Triton X-100 for 15 min, and washed with 16 TBST. After
washing (16PBS), cells were blocked with BSA in PBS for 1 hr.
HCS cells were incubated with anti-cytochrome c antibody or
anti-Bax antibody (clone 6A7) (BD Pharmingen, Palo Alto, CA),
for 1 hr. Cells were washed in 16TBST and incubated with the
corresponding secondary antibodies conjugated with Alexa Fluor
488 (Molecular Probes, Eugene, OR) for 1 hr. Slides were
mounted in DAPI-containing mounting vector shield and
examined under a fluorescence microscope (a Nikon E800 fitted
with an Olympus DP70 camera). Images were processed with the
Image-ProPlus image analysis software (Media Cybernetic).
Rat growth plate studies
Tibia growth plate samples were used from our previously
reported in vivo study in which 7-week-old male Sprague Dawley
rats (B&K Universal, Sollentuna, Sweden) were treated with Dexa
(5 mg/kg body weight; s.c.) for 7 days. The control group received
vehicle only [45]. Two sections, one from each group, were
mounted on each slide so that all samples were treated under the
same conditions.
Flourescence microscopy of metatarsal bones
Fetal rat metatarsal bones were cultured for 12 days with and
without Dexa (1 mM) as previously described [43]. Bones were
fixed in 4% formalin, and 5 mm-thick sections were mounted on
slides. For immunohistochemistry of active Bax (clone 6A7) and c-
terminus HSP60 (Santa Cruz Biotechnology, Santa Cruz, CA),
antigen retrieval was performed in citrate buffer (pH 6.0) for
15 min at 95–97uC. The sections were incubated with 10%
normal serum for 1 hr, followed by primary antibody at 4uC
overnight and secondary antibodies conjugated with Alexa 546
(Molecular Probes Inc., Eugene, Oregon, USA) for 1 hr. Slides
were counterstained with DAPI for 15 min, and the resulting
fluorescent signals detected by fluorescence microscopy (a Nikon
E800 fitted with an Olympus DP70 camera).
Quantitative histology of the growth plates
Histological evaluations were performed as previously described
[17,46]. Tibia and femur sections from all groups were mounted
on the same slides and stained with Alcian blue/van Gieson stain
to detect any changes in the matrix [47] [48]. Digital images of
Alcian Blue- and van Gieson-stained growth plate sections were
collected, and all histological measurements were performed
within the central two-thirds of the growth plate using the
Olympus MicroImage
TM software
4.0 (Olympus Optical Co.,
Hamburg, Germany). Fifteen measurements were taken from
each sample of the growth plate to determine the growth plate
height.
Statistical analysis
All data are presented as mean values 6 SEM. Differences
between groups were tested using one-way analysis of variance
(ANOVA) followed by the Holm-Sidak post-hoc test.
Supporting Information
Figure S1 Chondrocyte column density (columns per mm
growth plate width) in vehicle and Dexa-treated (2 mg/kg body
weight) wild type and BaxKO female mice analyzed after 28 days
treatment (n=5).
(TIFF)
Figure S2 Dexa induces growth retardation in cultured fetal rat
metatarsal bones. The bones were cultured with Dexa (1 mmol/L)
for 12 days and longitudinal bone growth was measured as
previously reported (36); (***p,0.001, n=7).
(TIF)
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